Posts

Vertex Pharmaceuticals announced Tuesday that the U.S. Food and Drug Administration has lifted its clinical hold on the company’s Phase I/II clinical trial of VX-880, a pancreatic islet cell replacement therapy for people with Type 1 diabetes (TID).